Modular therapy approach in metastatic castration-refractory prostate cancerWALTER, B; ROGENHOFER, S; VOGELHUBER, M et al.World journal of urology (Print). 2010, Vol 28, Num 6, pp 745-750, issn 0724-4983, 6 p.Article

Serum Prosaposin Levels Are Increased in Patients With Advanced Prostate CancerKOOCHEKPOUR, Shahriar; SIYI HU; VELLASCO-GONZALEZ, Cruz et al.The Prostate. 2012, Vol 72, Num 3, pp 253-269, issn 0270-4137, 17 p.Article

Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate CancerBECKETT, Robert D; RODEFFER, Kathryn M; SNODGRASS, Rachel et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 7-8, pp 1016-1024, issn 1060-0280, 9 p.Article

Integration of immunotherapy into the management of advanced prostate cancerKANTOFF, Philip; HIGANO, Celestia S.Urologic oncology. 2012, Vol 30, Num 5, issn 1078-1439, S41-S47, SUPArticle

Life after failure of traditional androgen deprivation therapySCHELLHAMMER, Paul.Urologic oncology. 2012, Vol 30, Num 4, issn 1078-1439, S10-S14, SUPConference Paper

Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)ADENIJI, Adegoke O; TWENTER, Barry M; BYRNS, Michael C et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 5, pp 1464-1468, issn 0960-894X, 5 p.Article

A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. CommentarySZMULEWITZ, Russell; MOHILE, Supriya; POSADAS, Edwin et al.European urology. 2009, Vol 56, Num 1, pp 97-104, issn 0302-2838, 8 p.Article

Beyond castration and chemotherapy: Novel approaches to targeting androgen-driven pathwaysSUMANTA KUMAR PAL; TWARDOWSKI, Przemyslaw; JOSEPHSON, David Y et al.Maturitas (Amsterdam). 2009, Vol 64, Num 2, pp 61-66, issn 0378-5122, 6 p.Article

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancerJESKE, Stephanie; TAGAWA, Scott T; OLOWOKURE, Olugbenga et al.Urologic oncology. 2011, Vol 29, Num 6, pp 676-681, issn 1078-1439, 6 p.Article

Upregulated FGFRI expression is associated with the transition of hormone-naive to castrate-resistant prostate cancerARMSTRONG, K; AHMAD, I; KALNA, G et al.British journal of cancer. 2011, Vol 105, Num 9, pp 1362-1369, issn 0007-0920, 8 p.Article

Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpointBIRTLE, Alison.Expert review of anticancer therapy. 2013, Vol 13, Num 1, pp 89-99, issn 1473-7140, 11 p.Article

Development of a Castrate Resistant Transplant Tumor Model of Prostate CancerELLIS, Leigh; LEHET, Kristin; RAMAKRISHNAN, Swathi et al.The Prostate. 2012, Vol 72, Num 6, pp 587-591, issn 0270-4137, 5 p.Article

Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancerDORFF, T. B; CRAWFORD, E. D.Annals of oncology. 2013, Vol 24, Num 1, pp 31-38, issn 0923-7534, 8 p.Article

Overexpression of the VSSC-Associated CAM, Beta-2, Enhances LNCaP Cell Metastasis Associated BehaviorJANSSON, Keith H; LYNCH, Jill E; LEPORI-BUI, Nadia et al.The Prostate. 2012, Vol 72, Num 10, pp 1080-1092, issn 0270-4137, 13 p.Article

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancerMAHON, K. L; QU, W; GURNE, H et al.British journal of cancer. 2014, Vol 111, Num 9, pp 1802-1809, issn 0007-0920, 8 p.Article

Expression of Cancer/Testis Antigens in Prostate Cancer Is Associated With Disease ProgressionSUYAMA, Takahito; SHIRAISHI, Takumi; YU ZENG et al.The Prostate. 2010, Vol 70, Num 16, pp 1778-1787, issn 0270-4137, 10 p.Article

Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II studyMOHAMMAD REZA SAFARINEJAD.Urologic oncology. 2010, Vol 28, Num 1, pp 21-27, issn 1078-1439, 7 p.Article

Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptorMACKENZIE, Lewis; MCCALL, Pamela; MACKAY, Simon et al.Human pathology. 2012, Vol 43, Num 9, pp 1491-1500, issn 0046-8177, 10 p.Article

A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting av Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After ChemotherapyWIRTH, Manfred; HEIDENREICH, Axel; LANNERT, Heinrich et al.European urology. 2014, Vol 65, Num 5, pp 897-904, issn 0302-2838, 8 p.Article

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSRIDHAR, Srikala S; CANIL, Christina M; ZWIEBEL, James A et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 4, pp 927-933, issn 0344-5704, 7 p.Article

Increased TGF-β1-Mediated Suppression of Growth and Motility in Castrate-Resistant Prostate Cancer Cells is Consistent With Smad2/3 SignalingMILES, Fayth L; TUNG, Navpreet S; AGUIAR, Adam A et al.The Prostate. 2012, Vol 72, Num 12, pp 1339-1350, issn 0270-4137, 12 p.Article

A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men With Castrate-Resistant Prostate Cancer: Results From Cancer and Leukemia Group B Study 90006PICUS, Joel; HALABI, Susan; KELLY, W. Kevin et al.Cancer. 2011, Vol 117, Num 3, pp 526-533, issn 0008-543X, 8 p.Article

Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate CancerGARCIA, Jorge A; HUTSON, Thomas E; SHEPARD, Dale et al.Cancer. 2011, Vol 117, Num 4, pp 752-757, issn 0008-543X, 6 p.Article

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancerMUKHERJEE, R; MCGUINNESS, D. H; MCCALL, P et al.British journal of cancer. 2011, Vol 104, Num 12, pp 1920-1928, issn 0007-0920, 9 p.Article

Novel strategies in the treatment of castration-resistant prostate cancer (Review)MARECH, Ilaria; VACCA, Angelo; RANIERI, Girolamo et al.International journal of oncology. 2012, Vol 40, Num 5, pp 1320-1327, issn 1019-6439, 8 p.Article